Company / Return on Equity (ROE)
BioLife Solutions, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-1.2%
FY2025
5-year range
-38.4% / -1.2%
FY2021-FY2025
Trend
+78.5%
vs FY2024
Sector context
#90 of 147
Health Care
What the data says
BioLife Solutions, Inc. reports negative total equity of -1.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-1.2% in FY2025 with a 5-year CAGR of -2.2%.
Improved from -20.1% to -1.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +37.1pp
- 5-Year Change
- -2.2pp
- 10-Year Change
- -
Sector benchmark
#90 of 147 in Health CareTop 61% of 147This company -1.2% Sector average -3.1%
▼
+60.3% above sector average
Key checks
Key Insights
- BioLife Solutions, Inc.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 78.5% year-over-year.
- Currently 1.9pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1.2% | +78.5% |
| FY2024 | -5.8% | +71.3% |
| FY2023 | -20.1% | +47.5% |
| FY2022 | -38.4% | -1964.0% |
| FY2021 | -1.9% | -291.8% |
| FY2020 | 1.0% | +125.4% |
| FY2019 | -3.8% | -111.5% |
| FY2018 | 33.3% | - |
| FY2017 | - | - |
| FY2016 | -217.1% | -338.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026